Keryx Biopharmaceuticals to Present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7
March 09 2016 - 7:46PM
Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical
company focused on bringing innovative medicines to market for
people with renal disease, today announced it will present at the
Cowen and Company 36th Annual Health Care Conference in Boston, MA
on Monday, March 7, 2016 at 3:20 p.m. EST.
A live audio webcast of the presentation will be accessible from
Keryx’s website at http://investors.keryx.com within the Investor
Relations section under the “webcasts and presentations” page. An
archived version of the webcast will be available for at least 15
days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc. Keryx
Biopharmaceuticals, with headquarters in Boston, is focused on
bringing innovative medicines to market for people with renal
disease. In December 2014, the company launched its first
FDA-approved product, Auryxia™ (ferric citrate) for the control of
elevated serum phosphorus levels, or hyperphosphatemia, in patients
with chronic kidney disease (CKD) on dialysis, in the United
States. In January 2014, ferric citrate was approved for the
treatment of patients with all stages of CKD in Japan, where it is
being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco
Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the
European Commission granted European market authorization for
Fexeric® (ferric citrate coordination complex) for the control of
hyperphosphatemia in adults with non-dialysis and
dialysis-dependent chronic kidney disease. For more information
about Keryx, please visit www.keryx.com
KERYX CONTACT:
Lora Pike
Senior Director, Investor Relations
T: 617-466-3511
lora.pike@keryx.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2024 to May 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From May 2023 to May 2024